Kang-shuai Li

107 West Wenhua Road
Jinan, 250012, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer.

ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer.

Journal: World journal of surgical oncology

Published: August 17, 2025

PTPN9 dephosphorylates IGF1RY1165/1166 and alleviates IGF1R-mediated resistance to tyrosine kinase inhibitor in cholangiocarcinoma.

PTPN9 dephosphorylates IGF1RY1165/1166 and alleviates IGF1R-mediated resistance to tyrosine kinase inhibitor in cholangiocarcinoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 10, 2025

Prognostic analysis of lymph node resection and liver resection for T1b and T2 gallbladder cancer: a multi-center retrospective study.

Prognostic analysis of lymph node resection and liver resection for T1b and T2 gallbladder cancer: a multi-center retrospective study.

Journal: HPB : the official journal of the International Hepato Pancreato Biliary Association

Published: December 29, 2024

EEF1AKMT4-eEF1A2 synergistically facilitates the progression of GBC by promoting ribosomal protein output.

EEF1AKMT4-eEF1A2 synergistically facilitates the progression of GBC by promoting ribosomal protein output.

Journal: Genes & diseases

Published: November 03, 2024

Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma.

Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma.

Journal: Frontiers in pharmacology

Published: May 23, 2024

Prognostic nomogram for patients with advanced unresectable hepatocellular carcinoma treated with TAE combined with HAIC.

Prognostic nomogram for patients with advanced unresectable hepatocellular carcinoma treated with TAE combined with HAIC.

Journal: Frontiers in pharmacology

Published: May 02, 2024

SMAD4 regulates the progression of cholangiocarcinoma by modulating the expression of STING1.

SMAD4 regulates the progression of cholangiocarcinoma by modulating the expression of STING1.

Journal: Journal of cellular and molecular medicine

Published: June 01, 2023

Case report: Obstructive jaundice caused by biliary cystadenoma.

Case report: Obstructive jaundice caused by biliary cystadenoma.

Journal: Frontiers in oncology

Published: February 14, 2023

Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis.

Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis.

Journal: Frontiers in oncology

Published: October 20, 2022

Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers.

Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers.

Journal: Frontiers in immunology

Published: September 21, 2022

Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model.

Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model.

Journal: Experimental hematology & oncology

Published: January 10, 2022

PTP-MEG2 regulates quantal size and fusion pore opening through two distinct structural bases and substrates.

PTP-MEG2 regulates quantal size and fusion pore opening through two distinct structural bases and substrates.

Journal: EMBO reports

Published: November 20, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026